The Recent Progress in RSV Vaccine Technology

Author(s): Andrew Fretzayas, Anna Papadopoulou, Doxa Kotzia, Maria Moustaki.

Journal Name: Recent Patents on Anti-Infective Drug Discovery

Volume 7 , Issue 3 , 2012

Become EABM
Become Reviewer


The most effective way to control RSV infection would be the development of an expedient and safe vaccine. Subunit vaccines, live attenuated RSV vaccines, plasmid DNA vaccines have been tested either in human or in mouse models without reaching the ultimate goal of efficacy and safety, at least in humans. Viruses such as adenovirus, sendai virus, measles virus were also used as vectors for the generation of RSV vaccines with promising results in animal models. Recent patents describe new techniques for the generation of candidate vaccines. These patents include virus like particles as vaccine platforms, recombinant RSVs or modified RSV F protein as component of the vaccine. Despite the number of the candidate vaccines, the new RSV vaccines should overcome many obstacles before being established as effective vaccines for the control of RSV infections especially for the young infants who are more susceptible to the virus.

Keywords: Adjuvants, DNA vaccines, live attenuated vaccines, subunit vaccines, RSV, RSV vaccine, VIRAL VECTORS, Measles vaccine, REPLICON VECTORS

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [237 - 241]
Pages: 5
DOI: 10.2174/157489112803522002
Price: $58

Article Metrics

PDF: 7